B BETA BIONICS INC
| Market Cap | $440.71M |
| P/E Ratio | — |
| Forward P/E | -5.12 |
| Dividend Yield | — |
| Beta | — |
| 52W Range | $9.71 - $31.99 |
| # Hedge Funds | 1 |
| Sector | Healthcare |
| Industry | Medical Devices |
Hedge Fund Ownership
| Investor 1 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|---|---|---|---|
| First Eagle Investment Management First Eagle Investment Management | 0.01% | $7.73M | 253,702 | Add 8.79% |
Insider Trading
| Insider Name of the company insider who made the trade 39 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Hopman MarkChief Commercial Officer | Sale | 353 | $11.57 | $4.08K | 04 Mar 2026 | 05 Mar 2026 |
| Mensinger MikeChief Product Officer | Sale | 1,064 | $12.36 | $13.15K | 02 Mar 2026 | 03 Mar 2026 |
| Feider StephenChief Financial Officer | Sale | 1,428 | $12.36 | $17.65K | 02 Mar 2026 | 03 Mar 2026 |
| Saint SeanPresident & CEO | Sale | 3,384 | $12.36 | $41.83K | 02 Mar 2026 | 03 Mar 2026 |
| Russell Steven JonChief Medical Officer | Sale | 1,026 | $12.36 | $12.68K | 02 Mar 2026 | 03 Mar 2026 |
| Hopman MarkChief Commercial Officer | Sale | 834 | $12.36 | $10.31K | 02 Mar 2026 | 03 Mar 2026 |
| Mensinger MikeChief Product Officer | Sale | 2,200 | $30.10 | $66.22K | 06 Jan 2026 | 07 Jan 2026 |
| Mike MensingerChief Product Officer | Sale | 2,200 | $30.10 | $66.22K | 06 Jan 2026 | 07 Jan 2026 |
| Feider StephenChief Financial Officer | Sale | 20,000 | $29.53 | $590.68K | 02 Jan 2026 | 05 Jan 2026 |
| Mensinger MikeChief Product Officer | Sale | 7,200 | $29.56 | $212.83K | 02 Jan 2026 | 05 Jan 2026 |
| Mensinger MikeChief Product Officer | Sale | 600 | $30.20 | $18.12K | 02 Jan 2026 | 05 Jan 2026 |
| Mike MensingerChief Product Officer | Sale | 600 | $30.20 | $18.12K | 02 Jan 2026 | 05 Jan 2026 |
| Stephen FeiderChief Financial Officer | Sale | 20,000 | $29.53 | $590.68K | 02 Jan 2026 | 05 Jan 2026 |
| Mike MensingerChief Product Officer | Sale | 7,200 | $29.56 | $212.83K | 02 Jan 2026 | 05 Jan 2026 |
| Hopman MarkChief Commercial Officer | Sale | 2,061 | $30.66 | $63.19K | 04 Dec 2025 | 02 Dec 2025 |
| Hopman MarkChief Commercial Officer | Sale | 856 | $29.34 | $25.11K | 02 Dec 2025 | 02 Dec 2025 |
| Russell Steven JonChief Medical Officer | Sale | 1,025 | $29.34 | $30.07K | 02 Dec 2025 | 02 Dec 2025 |
| Feider StephenChief Financial Officer | Sale | 1,427 | $29.34 | $41.86K | 02 Dec 2025 | 04 Dec 2025 |
| Saint SeanPresident & CEO | Sale | 3,278 | $29.34 | $96.16K | 02 Dec 2025 | 04 Dec 2025 |
| Mensinger MikeChief Product Officer | Sale | 1,063 | $29.34 | $31.18K | 02 Dec 2025 | 04 Dec 2025 |
| Sean SaintPresident & CEO | Sale | 3,278 | $29.34 | $96.16K | 02 Dec 2025 | 04 Dec 2025 |
| Stephen FeiderChief Financial Officer | Sale | 1,427 | $29.34 | $41.86K | 02 Dec 2025 | 04 Dec 2025 |
| Mike MensingerChief Product Officer | Sale | 1,063 | $29.34 | $31.18K | 02 Dec 2025 | 04 Dec 2025 |
| Palasis Maria | Sale | 500 | $29.96 | $14.98K | 01 Dec 2025 | 02 Dec 2025 |
| Palasis Maria | Sale | 906 | $29.33 | $26.57K | 01 Dec 2025 | 02 Dec 2025 |
| Lezack Adam | Sale | 500 | $29.91 | $14.96K | 01 Dec 2025 | 02 Dec 2025 |
| Lezack Adam | Sale | 906 | $29.35 | $26.59K | 01 Dec 2025 | 02 Dec 2025 |
| Adam LezackDirector | Sale | 500 | $29.91 | $14.96K | 01 Dec 2025 | 02 Dec 2025 |
| Adam LezackDirector | Sale | 906 | $29.35 | $26.59K | 01 Dec 2025 | 02 Dec 2025 |
| Maria PalasisDirector | Sale | 500 | $29.96 | $14.98K | 01 Dec 2025 | 02 Dec 2025 |
| Maria PalasisDirector | Sale | 906 | $29.33 | $26.57K | 01 Dec 2025 | 02 Dec 2025 |
| Lezack Adam | Sale | 38 | $27.70 | $1.05K | 31 Oct 2025 | 05 Nov 2025 |
| Lezack Adam | Sale | 1,368 | $26.85 | $36.73K | 31 Oct 2025 | 05 Nov 2025 |
| Palasis Maria | Sale | 119 | $27.45 | $3.27K | 31 Oct 2025 | 05 Nov 2025 |
| Palasis Maria | Sale | 1,287 | $26.86 | $34.57K | 31 Oct 2025 | 05 Nov 2025 |
| Maria PalasisDirector | Sale | 119 | $27.45 | $3.27K | 31 Oct 2025 | 05 Nov 2025 |
| Maria PalasisDirector | Sale | 1,287 | $26.86 | $34.57K | 31 Oct 2025 | 05 Nov 2025 |
| Adam LezackDirector | Sale | 38 | $27.70 | $1.05K | 31 Oct 2025 | 05 Nov 2025 |
| Adam LezackDirector | Sale | 1,368 | $26.85 | $36.73K | 31 Oct 2025 | 05 Nov 2025 |
Frequently Asked Questions
What is BBNX stock price today?
BETA BIONICS INC (BBNX) is currently trading at $9.93. The stock has a 52-week range of $9.71 to $31.99 and a market capitalization of $440.71M.
Is BBNX a good stock to buy in 2026?
BETA BIONICS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of -7.8%. 1 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling BBNX stock?
There have been 39 insider transactions for BBNX in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has BBNX stock performed over the past year?
BETA BIONICS INC (BBNX) has returned -7.8% over the past 12 months. The stock traded between $9.71 and $31.99 during this period, and is currently at $9.93.
Which hedge funds own BBNX (BETA BIONICS INC)?
1 tracked hedge funds currently hold BBNX in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is BBNX's market cap and valuation?
BETA BIONICS INC (BBNX) has a market capitalization of $440.71M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is BBNX's revenue and profitability?
BETA BIONICS INC reported revenue of $100.25M with net income of N/A and a profit margin of N/A. The stock has a beta of N/A.
What sector is BBNX in and who are its biggest institutional holders?
BETA BIONICS INC (BBNX) operates in the Healthcare sector. It is held by 1 tracked hedge funds. See the ownership table above for the complete list.